← InnoCare Pharma Ltd. A overview

InnoCare Pharma Ltd. A vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

InnoCare Pharma Ltd. A (688428.CG)

Q3 2026
▲4

InnoCare's pipeline wins and first-half profit mark a turning point

  • Orelabrutinib Phase 3 data published, confirming best-in-class profile Published Phase 3 results show orelabrutinib cut the risk of CLL/SLL worsening or death by 68% versus older chemo-immunotherapy, with a strong safety profile. It is already approved and reimbursed in China, so this backs up existing sales and makes future growth more believable.

    Confirms the core marketed drug's clinical strength, supporting revenue durability.

  • Two TYK2 inhibitors hit Phase 3 goals in skin diseases Soficitinib met its main goal in a Phase 3 atopic dermatitis trial, and fadeucravacitinib did the same in plaque psoriasis. Both are oral drugs for large, chronic skin conditions, so success widens the company's future revenue beyond its blood-cancer drugs.

    Adds two new late-stage assets that could become major future sellers.

  • Mesutoclax combination gets fast-track status and Phase 3 clearance China's drug regulator gave the orelabrutinib-mesutoclax combo Breakthrough Therapy Designation in lymphoma, and cleared a head-to-head Phase 3 trial of mesutoclax plus azacitidine in newly diagnosed AML. Faster reviews and a pivotal trial shorten the path to new approvals.

    Regulatory acceleration de-risks and speeds up a key next-generation pipeline drug.

  • First-half 2026 results show 55.5% revenue growth and a profit Revenue rose 55.5% to RMB 1.1 billion and the company swung to a RMB 239.7 million profit, helped by orelabrutinib and new launches. With about RMB 8.4 billion in cash, it can fund its pipeline without needing to raise money soon.

    The profit turnaround and cash pile are the clearest sign the business is now self-funding.

August 2026
▲4

InnoCare's pipeline wins and first-half profit mark a turning point

  • Orelabrutinib Phase 3 data published, confirming best-in-class profile Published Phase 3 results show orelabrutinib cut the risk of CLL/SLL worsening or death by 68% versus older chemo-immunotherapy, with a strong safety profile. It is already approved and reimbursed in China, so this backs up existing sales and makes future growth more believable.

    Confirms the core marketed drug's clinical strength, supporting revenue durability.

  • Two TYK2 inhibitors hit Phase 3 goals in skin diseases Soficitinib met its main goal in a Phase 3 atopic dermatitis trial, and fadeucravacitinib did the same in plaque psoriasis. Both are oral drugs for large, chronic skin conditions, so success widens the company's future revenue beyond its blood-cancer drugs.

    Adds two new late-stage assets that could become major future sellers.

  • Mesutoclax combination gets fast-track status and Phase 3 clearance China's drug regulator gave the orelabrutinib-mesutoclax combo Breakthrough Therapy Designation in lymphoma, and cleared a head-to-head Phase 3 trial of mesutoclax plus azacitidine in newly diagnosed AML. Faster reviews and a pivotal trial shorten the path to new approvals.

    Regulatory acceleration de-risks and speeds up a key next-generation pipeline drug.

  • First-half 2026 results show 55.5% revenue growth and a profit Revenue rose 55.5% to RMB 1.1 billion and the company swung to a RMB 239.7 million profit, helped by orelabrutinib and new launches. With about RMB 8.4 billion in cash, it can fund its pipeline without needing to raise money soon.

    The profit turnaround and cash pile are the clearest sign the business is now self-funding.

Latest
▲4

InnoCare's pipeline wins and first-half profit mark a turning point

  • Orelabrutinib Phase 3 data published, confirming best-in-class profile Published Phase 3 results show orelabrutinib cut the risk of CLL/SLL worsening or death by 68% versus older chemo-immunotherapy, with a strong safety profile. It is already approved and reimbursed in China, so this backs up existing sales and makes future growth more believable.

    Confirms the core marketed drug's clinical strength, supporting revenue durability.

  • Two TYK2 inhibitors hit Phase 3 goals in skin diseases Soficitinib met its main goal in a Phase 3 atopic dermatitis trial, and fadeucravacitinib did the same in plaque psoriasis. Both are oral drugs for large, chronic skin conditions, so success widens the company's future revenue beyond its blood-cancer drugs.

    Adds two new late-stage assets that could become major future sellers.

  • Mesutoclax combination gets fast-track status and Phase 3 clearance China's drug regulator gave the orelabrutinib-mesutoclax combo Breakthrough Therapy Designation in lymphoma, and cleared a head-to-head Phase 3 trial of mesutoclax plus azacitidine in newly diagnosed AML. Faster reviews and a pivotal trial shorten the path to new approvals.

    Regulatory acceleration de-risks and speeds up a key next-generation pipeline drug.

  • First-half 2026 results show 55.5% revenue growth and a profit Revenue rose 55.5% to RMB 1.1 billion and the company swung to a RMB 239.7 million profit, helped by orelabrutinib and new launches. With about RMB 8.4 billion in cash, it can fund its pipeline without needing to raise money soon.

    The profit turnaround and cash pile are the clearest sign the business is now self-funding.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

© 2026 MarketIVWhy